Caribou Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CRBU Nasdaq 8731 https://www.cariboubio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Caribou Biosciences Inc

Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma - Mar 29th, 2023 12:00 pm
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients - Mar 29th, 2023 12:00 pm
Caribou Biosciences Full Year 2022 Earnings: Beats Expectations - Mar 11th, 2023 12:31 pm
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates - Mar 10th, 2023 12:25 am
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Mar 9th, 2023 10:09 pm
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference - Mar 8th, 2023 9:05 pm
Here's Why We're Not Too Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation - Mar 7th, 2023 5:10 pm
Caribou Biosciences to Participate in Upcoming Investor Conferences - Feb 1st, 2023 9:05 pm
Investors in Caribou Biosciences (NASDAQ:CRBU) from a year ago are still down 46%, even after 11% gain this past week - Jan 6th, 2023 4:01 pm
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 9:05 pm
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress - Dec 12th, 2022 1:01 pm
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy - Dec 12th, 2022 1:00 pm
Positive week for Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional investors who lost 50% over the past year - Dec 7th, 2022 2:52 pm
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy - Nov 29th, 2022 2:00 pm
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma - Nov 21st, 2022 2:00 pm
Growth Investors: Industry Analysts Just Upgraded Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts By 27% - Nov 9th, 2022 12:57 pm
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates - Nov 8th, 2022 10:15 pm
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 8th, 2022 9:00 pm
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting - Nov 3rd, 2022 1:00 pm
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022 - Oct 18th, 2022 1:00 pm